FEATURED COMPANIES
- Eli Lilly and Company
- F. Hoffmann-La Roche Ltd
- Pfizer Inc.
- Sanofi
1h Free Analyst Time
Speak directly to the analyst to clarify any post sales queries you may have.
Cholangiocarcinoma is one of the rare types of cancers globally, as a result, the market does not have approved therapies in abundance. The dominance of these drugs is affecting the interest of new vendors to conduct research on developing novel therapies. To overcome this challenge, several research institutes are coming up with various programs to treat patients with intrahepatic cholangiocarcinoma and extrahepatic cholangiocarcinoma.
The support from the institute is also coming in the form of new chemotherapy combinations for treating both types of cholangiocarcinoma. Similarly, various other research institutions are also working on providing treatment to the patients, and the increasing support from these institutes is expected to contribute significantly to the growth of the global cholangiocarcinoma therapeutics market during the forecast period. The analysts have predicted that the cholangiocarcinoma therapeutics market will register a CAGR of almost 6% by 2023.
Market Overview
Growing usage of combination there
The global cholangiocarcinoma therapeutics market has a limited number of treatment options, among which the most preferred treatment option is surgeries due to the lack of efficacy of therapeutics in the late stages of the disease. To overcome this, the market is witnessing an increase in the use of combination of chemotherapies to treat the disease.
Dominance of surgery
The global cholangiocarcinoma therapeutics market faces a heavy threat from surgeries, as they are currently the most preferred treatment option available to the patients. As a result, surgeries are gaining popularity for the treatment of both intrahepatic cholangiocarcinoma and extrahepatic cholangiocarcinoma, which is expected to have a negative impact on the growth of the global cholangiocarcinoma therapeutics market during the forecast period.
For the detailed list of factors that will drive and challenge the growth of the cholangiocarcinoma therapeutics market during the 2019-2023, view this report.
Competitive Landscape
The market appears to be fairly concentrated and with the presence of few vendors. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market’s competitive landscape and offering information on the products offered by companies.
The support from the institute is also coming in the form of new chemotherapy combinations for treating both types of cholangiocarcinoma. Similarly, various other research institutions are also working on providing treatment to the patients, and the increasing support from these institutes is expected to contribute significantly to the growth of the global cholangiocarcinoma therapeutics market during the forecast period. The analysts have predicted that the cholangiocarcinoma therapeutics market will register a CAGR of almost 6% by 2023.
Market Overview
Growing usage of combination there
The global cholangiocarcinoma therapeutics market has a limited number of treatment options, among which the most preferred treatment option is surgeries due to the lack of efficacy of therapeutics in the late stages of the disease. To overcome this, the market is witnessing an increase in the use of combination of chemotherapies to treat the disease.
Dominance of surgery
The global cholangiocarcinoma therapeutics market faces a heavy threat from surgeries, as they are currently the most preferred treatment option available to the patients. As a result, surgeries are gaining popularity for the treatment of both intrahepatic cholangiocarcinoma and extrahepatic cholangiocarcinoma, which is expected to have a negative impact on the growth of the global cholangiocarcinoma therapeutics market during the forecast period.
For the detailed list of factors that will drive and challenge the growth of the cholangiocarcinoma therapeutics market during the 2019-2023, view this report.
Competitive Landscape
The market appears to be fairly concentrated and with the presence of few vendors. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market’s competitive landscape and offering information on the products offered by companies.
Note: Product cover images may vary from those shown
FEATURED COMPANIES
- Eli Lilly and Company
- F. Hoffmann-La Roche Ltd
- Pfizer Inc.
- Sanofi
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 07: MARKET SEGMENTATION BY TYPE
PART 09: GEOGRAPHIC LANDSCAPE
PART 12: VENDOR LANDSCAPE
Exhibit 01: Global oncology therapeutics market
Exhibit 02: Segments of global oncology therapeutics market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Market definition - Inclusions and exclusions checklist
Exhibit 06: Market size 2018
Exhibit 07: Global market
Exhibit 08: Global market
Exhibit 09: Five forces analysis 2018
Exhibit 10: Five forces analysis 2023
Exhibit 11: Bargaining power of buyers
Exhibit 12: Bargaining power of suppliers
Exhibit 13: Threat of new entrants
Exhibit 14: Threat of substitutes
Exhibit 15: Threat of rivalry
Exhibit 16: Market condition - Five forces 2018
Exhibit 17: Global cholangiocarcinoma therapeutics market pipeline
Exhibit 18: Global cholangiocarcinoma therapeutics market pipeline
Exhibit 19: Type - Market share 2018-2023 (%)
Exhibit 20: Comparison by type
Exhibit 21: Intrahepatic cholangiocarcinoma - Market size and forecast 2018-2023 ($ millions)
Exhibit 22: Intrahepatic cholangiocarcinoma - Year-over-year growth 2019-2023 (%)
Exhibit 23: Extrahepatic cholangiocarcinoma - Market size and forecast 2018-2023 ($ millions)
Exhibit 24: Extrahepatic cholangiocarcinoma - Year-over-year growth 2019-2023 (%)
Exhibit 25: Market opportunity by type
Exhibit 26: Customer landscape
Exhibit 27: Market share by geography 2018-2023 (%)
Exhibit 28: Geographic comparison
Exhibit 29: North America - Market size and forecast 2018-2023 ($ millions)
Exhibit 30: North America - Year-over-year growth 2019-2023 (%)
Exhibit 31: Europe - Market size and forecast 2018-2023 ($ millions)
Exhibit 32: Europe - Year-over-year growth 2019-2023 (%)
Exhibit 33: Asia - Market size and forecast 2018-2023 ($ millions)
Exhibit 34: Asia - Year-over-year growth 2019-2023 (%)
Exhibit 35: ROW - Market size and forecast 2018-2023 ($ millions)
Exhibit 36: ROW - Year-over-year growth 2019-2023 (%)
Exhibit 37: Key leading countries
Exhibit 38: Market opportunity
Exhibit 39: Impact of drivers and challenges
Exhibit 40: Vendor landscape
Exhibit 41: Landscape disruption
Exhibit 42: Vendors covered
Exhibit 43: Vendor classification
Exhibit 44: Market positioning of vendors
Exhibit 45: Bristol-Myers Squibb Company - Vendor overview
Exhibit 46: Bristol-Myers Squibb Company - Business segments
Exhibit 47: Bristol-Myers Squibb Company - Organizational developments
Exhibit 48: Bristol-Myers Squibb Company - Geographic focus
Exhibit 49: Bristol-Myers Squibb Company - Key offerings
Exhibit 50: Bristol-Myers Squibb Company - Key customers
Exhibit 51: Eli Lilly and Company - Vendor overview
Exhibit 52: Eli Lilly and Company - Business segments
Exhibit 53: Eli Lilly and Company - Organizational developments
Exhibit 54: Eli Lilly and Company - Geographic focus
Exhibit 55: Eli Lilly and Company - Segment focus
Exhibit 56: Eli Lilly and Company - Key offerings
Exhibit 57: Eli Lilly and Company - Key customers
Exhibit 58: F. Hoffmann-La Roche Ltd - Vendor overview
Exhibit 59: F. Hoffmann-La Roche Ltd - Business segments
Exhibit 60: F. Hoffmann-La Roche Ltd - Organizational developments
Exhibit 61: F. Hoffmann-La Roche Ltd - Geographic focus
Exhibit 62: F. Hoffmann-La Roche Ltd - Segment focus
Exhibit 63: F. Hoffmann-La Roche Ltd - Key offerings
Exhibit 64: F. Hoffmann-La Roche Ltd - Key customers
Exhibit 65: Pfizer Inc. - Vendor overview
Exhibit 66: Pfizer Inc. - Business segments
Exhibit 67: Pfizer Inc. - Organizational developments
Exhibit 68: Pfizer Inc. - Geographic focus
Exhibit 69: Pfizer Inc. - Segment focus
Exhibit 70: Pfizer Inc. - Key offerings
Exhibit 71: Pfizer Inc. - Key customers
Exhibit 72: Sanofi - Vendor overview
Exhibit 73: Sanofi - Business segments
Exhibit 74: Sanofi - Organizational developments
Exhibit 75: Sanofi - Geographic focus
Exhibit 76: Sanofi - Segment focus
Exhibit 77: Sanofi - Key offerings
Exhibit 78: Sanofi - Key customers
Exhibit 79: Validation techniques employed for market sizing
PART 02: SCOPE OF THE REPORT
- Preface
- Currency conversion rates for US$
- Market ecosystem
- Market characteristics
- Market segmentation analysis
- Market definition
- Market sizing 2018
- Market size and forecast 2018-2023
- Bargaining power of buyers
- Bargaining power of suppliers
- Threat of new entrants
- Threat of substitutes
- Threat of rivalry
- Market condition
PART 07: MARKET SEGMENTATION BY TYPE
- Market segmentation by type
- Comparison by type
- Intrahepatic cholangiocarcinoma - Market size and forecast 2018-2023
- Extrahepatic cholangiocarcinoma - Market size and forecast 2018-2023
- Market opportunity by type
PART 09: GEOGRAPHIC LANDSCAPE
- Geographic segmentation
- Geographic comparison
- North America - Market size and forecast 2018-2023
- Europe - Market size and forecast 2018-2023
- Asia - Market size and forecast 2018-2023
- ROW - Market size and forecast 2018-2023
- Key leading countries
- Market opportunity
- Market drivers
- Market challenges
PART 12: VENDOR LANDSCAPE
- Overview
- Landscape disruption
- Competitive scenario
- Vendors covered
- Vendor classification
- Market positioning of vendors
- Bristol-Myers Squibb Company
- Eli Lilly and Company
- F. Hoffmann-La Roche Ltd
- Pfizer Inc.
- Sanofi
- Research methodology
- List of abbreviations
Exhibit 01: Global oncology therapeutics market
Exhibit 02: Segments of global oncology therapeutics market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Market definition - Inclusions and exclusions checklist
Exhibit 06: Market size 2018
Exhibit 07: Global market
Exhibit 08: Global market
Exhibit 09: Five forces analysis 2018
Exhibit 10: Five forces analysis 2023
Exhibit 11: Bargaining power of buyers
Exhibit 12: Bargaining power of suppliers
Exhibit 13: Threat of new entrants
Exhibit 14: Threat of substitutes
Exhibit 15: Threat of rivalry
Exhibit 16: Market condition - Five forces 2018
Exhibit 17: Global cholangiocarcinoma therapeutics market pipeline
Exhibit 18: Global cholangiocarcinoma therapeutics market pipeline
Exhibit 19: Type - Market share 2018-2023 (%)
Exhibit 20: Comparison by type
Exhibit 21: Intrahepatic cholangiocarcinoma - Market size and forecast 2018-2023 ($ millions)
Exhibit 22: Intrahepatic cholangiocarcinoma - Year-over-year growth 2019-2023 (%)
Exhibit 23: Extrahepatic cholangiocarcinoma - Market size and forecast 2018-2023 ($ millions)
Exhibit 24: Extrahepatic cholangiocarcinoma - Year-over-year growth 2019-2023 (%)
Exhibit 25: Market opportunity by type
Exhibit 26: Customer landscape
Exhibit 27: Market share by geography 2018-2023 (%)
Exhibit 28: Geographic comparison
Exhibit 29: North America - Market size and forecast 2018-2023 ($ millions)
Exhibit 30: North America - Year-over-year growth 2019-2023 (%)
Exhibit 31: Europe - Market size and forecast 2018-2023 ($ millions)
Exhibit 32: Europe - Year-over-year growth 2019-2023 (%)
Exhibit 33: Asia - Market size and forecast 2018-2023 ($ millions)
Exhibit 34: Asia - Year-over-year growth 2019-2023 (%)
Exhibit 35: ROW - Market size and forecast 2018-2023 ($ millions)
Exhibit 36: ROW - Year-over-year growth 2019-2023 (%)
Exhibit 37: Key leading countries
Exhibit 38: Market opportunity
Exhibit 39: Impact of drivers and challenges
Exhibit 40: Vendor landscape
Exhibit 41: Landscape disruption
Exhibit 42: Vendors covered
Exhibit 43: Vendor classification
Exhibit 44: Market positioning of vendors
Exhibit 45: Bristol-Myers Squibb Company - Vendor overview
Exhibit 46: Bristol-Myers Squibb Company - Business segments
Exhibit 47: Bristol-Myers Squibb Company - Organizational developments
Exhibit 48: Bristol-Myers Squibb Company - Geographic focus
Exhibit 49: Bristol-Myers Squibb Company - Key offerings
Exhibit 50: Bristol-Myers Squibb Company - Key customers
Exhibit 51: Eli Lilly and Company - Vendor overview
Exhibit 52: Eli Lilly and Company - Business segments
Exhibit 53: Eli Lilly and Company - Organizational developments
Exhibit 54: Eli Lilly and Company - Geographic focus
Exhibit 55: Eli Lilly and Company - Segment focus
Exhibit 56: Eli Lilly and Company - Key offerings
Exhibit 57: Eli Lilly and Company - Key customers
Exhibit 58: F. Hoffmann-La Roche Ltd - Vendor overview
Exhibit 59: F. Hoffmann-La Roche Ltd - Business segments
Exhibit 60: F. Hoffmann-La Roche Ltd - Organizational developments
Exhibit 61: F. Hoffmann-La Roche Ltd - Geographic focus
Exhibit 62: F. Hoffmann-La Roche Ltd - Segment focus
Exhibit 63: F. Hoffmann-La Roche Ltd - Key offerings
Exhibit 64: F. Hoffmann-La Roche Ltd - Key customers
Exhibit 65: Pfizer Inc. - Vendor overview
Exhibit 66: Pfizer Inc. - Business segments
Exhibit 67: Pfizer Inc. - Organizational developments
Exhibit 68: Pfizer Inc. - Geographic focus
Exhibit 69: Pfizer Inc. - Segment focus
Exhibit 70: Pfizer Inc. - Key offerings
Exhibit 71: Pfizer Inc. - Key customers
Exhibit 72: Sanofi - Vendor overview
Exhibit 73: Sanofi - Business segments
Exhibit 74: Sanofi - Organizational developments
Exhibit 75: Sanofi - Geographic focus
Exhibit 76: Sanofi - Segment focus
Exhibit 77: Sanofi - Key offerings
Exhibit 78: Sanofi - Key customers
Exhibit 79: Validation techniques employed for market sizing
Note: Product cover images may vary from those shown
FEATURED COMPANIES
- Eli Lilly and Company
- F. Hoffmann-La Roche Ltd
- Pfizer Inc.
- Sanofi
Global Cholangiocarcinoma Therapeutics Market 2019-2023
The analyst recognizes the following companies as the key players in the global cholangiocarcinoma therapeutics market: Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche Ltd, Pfizer Inc., Sanofi.
Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is the launch of safe and effective drugs could help in hanging the treatment strategies and increase the revenue generated by the market.”
According to the report, one of the major drivers for this market is the growing usage of combination therapy.
Further, the report states that one of the major factors hindering the growth of this market is the lack of approved biologics.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
The analyst recognizes the following companies as the key players in the global cholangiocarcinoma therapeutics market: Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche Ltd, Pfizer Inc., Sanofi.
Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is the launch of safe and effective drugs could help in hanging the treatment strategies and increase the revenue generated by the market.”
According to the report, one of the major drivers for this market is the growing usage of combination therapy.
Further, the report states that one of the major factors hindering the growth of this market is the lack of approved biologics.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
- Bristol-Myers Squibb Company
- Eli Lilly and Company
- F. Hoffmann-La Roche Ltd
- Pfizer Inc.
- Sanofi
Note: Product cover images may vary from those shown
LOADING...
